{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:54Z","timestamp":1791331254608,"version":"4.3.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a G\n                    <jats:sub>0<\/jats:sub>\n                    marker (G\n                    <jats:sub>0<\/jats:sub>\n                    M), we narrow down CML LSCs as G\n                    <jats:sub>0<\/jats:sub>\n                    M- and CD27- double positive cells among the conventional CML LSCs. Whole transcriptome analysis reveals NF-\u03baB activation via inflammatory signals in imatinib-insensitive quiescent CML LSCs. Blocking NF-\u03baB signals by inhibitors of interleukin-1 receptor-associated kinase 1\/4 (IRAK1\/4 inhibitors) together with imatinib eliminates mouse and human CML LSCs. Intriguingly, IRAK1\/4 inhibitors attenuate PD-L1 expression on CML LSCs, and blocking PD-L1 together with imatinib also effectively eliminates CML LSCs in the presence of T cell immunity. Thus, IRAK1\/4 inhibitors can eliminate CML LSCs through inhibiting NF-\u03baB activity and reducing PD-L1 expression. Collectively, the combination of TKIs and IRAK1\/4 inhibitors is an attractive strategy to achieve a radical cure of CML.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-27928-8","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T06:02:59Z","timestamp":1641967379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8538-0916","authenticated-orcid":false,"given":"Yosuke","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4233-8806","authenticated-orcid":false,"given":"Reina","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-9003","authenticated-orcid":false,"given":"Terumasa","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-7996","authenticated-orcid":false,"given":"Shuhei","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-0130","authenticated-orcid":false,"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-5000","authenticated-orcid":false,"given":"Marito","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-5430","authenticated-orcid":false,"given":"Hitoshi","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-3188","authenticated-orcid":false,"given":"Tomofusa","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystelle","family":"Lamagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban S.","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-2332","authenticated-orcid":false,"given":"Ryoji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Goyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"27928_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"27928_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp, N. et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306, 239\u2013242 (1983).","journal-title":"Nature"},{"key":"27928_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"27928_CR4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","volume":"15","author":"D Cortez","year":"1997","unstructured":"Cortez, D., Reuther, G. & Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15, 2333\u20132342 (1997).","journal-title":"Oncogene"},{"key":"27928_CR5","doi-asserted-by":"publisher","first-page":"8629","DOI":"10.1038\/sj.onc.1206090","volume":"21","author":"R Ren","year":"2002","unstructured":"Ren, R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21, 8629\u20138642 (2002).","journal-title":"Oncogene"},{"key":"27928_CR6","doi-asserted-by":"crossref","unstructured":"Bedi, A., Zehnbauer, B. A. & Barber, J. P. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038\u20132044 (1994).","DOI":"10.1182\/blood.V83.8.2038.bloodjournal8382038"},{"key":"27928_CR7","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie, E. et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121, 4175\u20134183 (2013).","journal-title":"Blood"},{"key":"27928_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"JM Goldman","year":"2001","unstructured":"Goldman, J. M. & Melo, J. V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 344, 1084\u20131086 (2001).","journal-title":"New Engl. J. Med."},{"key":"27928_CR9","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"New Engl. J. Med."},{"key":"27928_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"27928_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong, S. & Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247\u2013306 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"27928_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"27928_CR13","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358\u20133363 (2008).","journal-title":"J. Clin. Oncol."},{"key":"27928_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.leu.2403649","volume":"19","author":"W Eisterer","year":"2005","unstructured":"Eisterer, W. et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19, 435\u2013441 (2005).","journal-title":"Leukemia"},{"key":"27928_CR15","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532\u20134539 (2006).","journal-title":"Blood"},{"key":"27928_CR16","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C. & Holyoake, T. L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34\u03e9 CML cells. Blood 109, 4016\u20134019 (2007).","journal-title":"Blood"},{"key":"27928_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","volume":"130","author":"G Cheloni","year":"2017","unstructured":"Cheloni, G. et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood 130, 655\u2013665 (2017).","journal-title":"Blood"},{"key":"27928_CR18","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"H Zhang","year":"2012","unstructured":"Zhang, H., Li, H., Xi, H. S. & Li, S. HIF1\u2423 is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 119, 2595\u20132607 (2012).","journal-title":"Blood"},{"key":"27928_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","volume":"24","author":"P Agarwal","year":"2019","unstructured":"Agarwal, P. et al. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells. Cell Stem Cell 24, 769\u2013784.e6 (2019).","journal-title":"Cell Stem Cell"},{"key":"27928_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.360","volume":"26","author":"E Weisberg","year":"2012","unstructured":"Weisberg, E. et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985\u2013990 (2012).","journal-title":"Leukemia"},{"key":"27928_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.stem.2020.04.005","volume":"27","author":"K Rothe","year":"2020","unstructured":"Rothe, K. et al. Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors. Cell Stem Cell 27, 1\u201315 (2020).","journal-title":"Cell Stem Cell"},{"key":"27928_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-06-2014","volume":"67","author":"M Holtz","year":"2007","unstructured":"Holtz, M., Forman, S. J. & Bhatia, R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 67, 1113\u20131120 (2007).","journal-title":"Cancer Res."},{"key":"27928_CR23","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"R Warfvinge","year":"2017","unstructured":"Warfvinge, R. et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood 129, 2384\u20132394 (2017).","journal-title":"Blood"},{"key":"27928_CR24","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012).","journal-title":"Blood"},{"key":"27928_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","volume":"23","author":"S Takeishi","year":"2013","unstructured":"Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347\u2013361 (2013).","journal-title":"Cancer Cell"},{"key":"27928_CR26","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","volume":"23","author":"A Burgess","year":"2004","unstructured":"Burgess, A. et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23, 6693\u20136701 (2004).","journal-title":"Oncogene"},{"key":"27928_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427\u2013442 (2010).","journal-title":"Cancer Cell"},{"key":"27928_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","volume":"7","author":"L Jin","year":"2008","unstructured":"Jin, L. et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7, 48\u201358 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"27928_CR29","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/sj.onc.1201411","volume":"15","author":"M Hamdane","year":"1997","unstructured":"Hamdane, M., David-Cordonnier, M.-H. & D\u2019Halluin, J. C. Activation of p65 NF-kB protein by p210BCR \u00b1 ABL in a myeloid cell line (P210BCR \u00b1 ABL activates p65 NF-kB). Oncogene 15, 2267\u20132275 (1997).","journal-title":"Oncogene"},{"key":"27928_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.12.7.968","volume":"12","author":"JY Reuther","year":"1998","unstructured":"Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M. & Baldwin, A. S. A requirement for NF-kB activation in Bcr\u2013Abl-mediated transformation. Genes Dev 12, 968\u2013981 (1998).","journal-title":"Genes Dev"},{"key":"27928_CR31","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","volume":"123","author":"M-Y Hsieh","year":"2014","unstructured":"Hsieh, M.-Y. & Etten, R. A. V. IKK-dependent activation of NF-kB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL. Blood 123, 2401\u20132411 (2014).","journal-title":"Blood"},{"key":"27928_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.leu.2403998","volume":"20","author":"D Cilloni","year":"2006","unstructured":"Cilloni, D. et al. The NF-jB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. Leukemia 20, 61\u201367 (2006).","journal-title":"Leukemia"},{"key":"27928_CR33","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang, B. et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood 128, 2671\u20132682 (2016).","journal-title":"Blood"},{"key":"27928_CR34","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H \u00c5gerstam","year":"2016","unstructured":"\u00c5gerstam, H. et al. IL1RAP antibodies block IL-1\u2013induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 128, 2683\u20132693 (2016).","journal-title":"Blood"},{"key":"27928_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen, G. W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90\u2013104 (2013).","journal-title":"Cancer Cell"},{"key":"27928_CR36","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41375-018-0112-2","volume":"32","author":"MM Hosseini","year":"2018","unstructured":"Hosseini, M. M. et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia 32, 2374\u20132387 (2018).","journal-title":"Leukemia"},{"key":"27928_CR37","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018\u20131023 (2000).","journal-title":"Nat. Med."},{"key":"27928_CR38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","volume":"103","author":"H-J Kolb","year":"2004","unstructured":"Kolb, H.-J., Schmid, C., Barrett, A. J. & Schendel, D. J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103, 767\u2013776 (2004).","journal-title":"Blood"},{"key":"27928_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood-2011-01-331009","volume":"119","author":"Y-F Lu","year":"2012","unstructured":"Lu, Y.-F. et al. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood 119, 273\u2013284 (2012).","journal-title":"Blood"},{"key":"27928_CR40","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson, L. et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE 8, e55818 (2013).","journal-title":"PLoS ONE"},{"key":"27928_CR41","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2015.26","volume":"29","author":"C Riether","year":"2015","unstructured":"Riether, C., Gschwend, T., Huguenin, A.-L., Sch\u00fcrch, C. M. & Ochsenbein, A. F. Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Leukemia 29, 1781\u20131785 (2015).","journal-title":"Leukemia"},{"key":"27928_CR42","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht, S., Sch\u00fcrch, C., Schwaller, J., Solenthaler, M. & Ochsenbein, A. F. Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression. Blood 114, 1528\u20131536 (2009).","journal-title":"Blood"},{"key":"27928_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep04012","volume":"4","author":"T Oki","year":"2015","unstructured":"Oki, T. et al. A novel cell-cycle-indicator, mVenus-p27K\u2212, identifies quiescent cells and visualizes G0\u2013G1 transition. Sci. Rep. 4, 4012 (2015).","journal-title":"Sci. Rep."},{"key":"27928_CR44","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1016\/j.celrep.2019.11.061","volume":"29","author":"T Fukushima","year":"2019","unstructured":"Fukushima, T. et al. Discrimination of dormant and active hematopoietic stem cells by G0 marker reveals dormancy regulation by cytoplasmic calcium. Cell Rep 29, 4144\u20134158 (2019).","journal-title":"Cell Rep"},{"key":"27928_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI45977","volume":"122","author":"C Sch\u00fcrch","year":"2012","unstructured":"Sch\u00fcrch, C., Riether, C., Matter, M. S., Tzankov, A. & Ochsenbein, A. F. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J. Clin. Invest. 122, 624\u2013638 (2012).","journal-title":"J. Clin. Invest."},{"key":"27928_CR46","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","volume":"123","author":"CI Kobayashi","year":"2014","unstructured":"Kobayashi, C. I. et al. The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 123, 2540\u20132549 (2014).","journal-title":"Blood"},{"key":"27928_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).","journal-title":"BMC Bioinformatics"},{"key":"27928_CR48","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.4049\/jimmunol.1203543","volume":"191","author":"R Ito","year":"2013","unstructured":"Ito, R. et al. Establishment of a human allergy model using human IL-3\/GM-CSF\u2013transgenic NOG mice. J. Immunol. 191, 2890\u20132899 (2013).","journal-title":"J. Immunol."},{"key":"27928_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"27928_CR50","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1084\/jem.194.8.1151","volume":"194","author":"Z Hao","year":"2001","unstructured":"Hao, Z. & Rajewsky, K. Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow. J. Exp. Med. 194, 1151\u20131164 (2001).","journal-title":"J. Exp. Med."},{"key":"27928_CR51","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E. et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J. Clin. Oncol. 34, 2333\u20132340 (2016).","journal-title":"J. Clin. Oncol."},{"key":"27928_CR52","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T Holyoake","year":"1999","unstructured":"Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056\u20132064 (1999).","journal-title":"Blood"},{"key":"27928_CR53","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","volume":"34","author":"R Kinstrie","year":"2020","unstructured":"Kinstrie, R. et al. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia 34, 1613\u20131625 (2020).","journal-title":"Leukemia"},{"key":"27928_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2019.05.019","volume":"25","author":"M Yamashita","year":"2019","unstructured":"Yamashita, M. & Passegu\u00e9, E. TNF-\u03b1 coordinates hematopoietic stem cell survival and myeloid regeneration. Cell Stem Cell 25, 357\u2013372 (2019).","journal-title":"Cell Stem Cell"},{"key":"27928_CR55","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","volume":"123","author":"KP Ng","year":"2014","unstructured":"Ng, K. P. et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood 123, 3316\u20133326 (2014).","journal-title":"Blood"},{"key":"27928_CR56","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1038\/onc.2017.85","volume":"36","author":"HS Madapura","year":"2017","unstructured":"Madapura, H. S. et al. Interferon \u03b3 is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene 36, 4619\u20134628 (2017).","journal-title":"Oncogene"},{"key":"27928_CR57","doi-asserted-by":"publisher","first-page":"e1065368","DOI":"10.1080\/2162402X.2015.1065368","volume":"5","author":"SAE Held","year":"2016","unstructured":"Held, S. A. E. et al. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. OncoImmunology 5, e1065368 (2016).","journal-title":"OncoImmunology"},{"key":"27928_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1189\/jlb.0313153","volume":"94","author":"S Muralidharan","year":"2013","unstructured":"Muralidharan, S. & Mandrekar, P. Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J. Leukoc. Biol. 94, 1167\u20131184 (2013).","journal-title":"J. Leukoc. Biol."},{"key":"27928_CR59","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1172\/JCI75821","volume":"125","author":"Z Li","year":"2015","unstructured":"Li, Z. et al. Inhibition of IRAK1\/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J. Clin. Invest. 125, 1081\u20131097 (2015).","journal-title":"J. Clin. Invest."},{"key":"27928_CR60","doi-asserted-by":"publisher","first-page":"33416","DOI":"10.18632\/oncotarget.26058","volume":"9","author":"JW Singer","year":"2018","unstructured":"Singer, J. W. et al. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget 9, 33416\u201333439 (2018).","journal-title":"Oncotarget"},{"key":"27928_CR61","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1084\/jem.20151074","volume":"212","author":"PN Kelly","year":"2015","unstructured":"Kelly, P. N. et al. Selective interleukin-1 receptor\u2013associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J. Exp. Med. 212, 2189\u20132201 (2015).","journal-title":"J. Exp. Med."},{"key":"27928_CR62","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith, M. A. et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat. Cell Biol. 21, 640\u2013650 (2019).","journal-title":"Nat. Cell Biol."},{"key":"27928_CR63","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2013.180","volume":"27","author":"Y Wei","year":"2013","unstructured":"Wei, Y. et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27, 1832\u20131840 (2013).","journal-title":"Leukemia"},{"key":"27928_CR64","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ijc.24294","volume":"125","author":"N Lounnas","year":"2009","unstructured":"Lounnas, N. et al. NF-\u03baB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308\u2013317 (2009).","journal-title":"Int. J. Cancer"},{"key":"27928_CR65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327\u2013334 (2014).","journal-title":"Nature"},{"key":"27928_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev-pathol-012615-044414","volume":"11","author":"J Hoggatt","year":"2016","unstructured":"Hoggatt, J., Kfoury, Y. & Scadden, D. T. Hematopoietic stem cell niche in health and disease. Annu. Rev. Pathol. Mech. Dis. 11, 555\u2013581 (2016).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"27928_CR67","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577\u2013592 (2012).","journal-title":"Cancer Cell"},{"key":"27928_CR68","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","volume":"85","author":"R Bhatia","year":"1995","unstructured":"Bhatia, R., McGlave, P., Dewald, G., Blazar, B. & Verfaillie, C. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85, 3636\u20133645 (1995).","journal-title":"Blood"},{"key":"27928_CR69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285\u2013299 (2013).","journal-title":"Cell Stem Cell"},{"key":"27928_CR70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/1744666X.2015.1019474","volume":"11","author":"V Vonka","year":"2015","unstructured":"Vonka, V. & Petr\u00e1\u010dkov\u00e1, M. Immunology of chronic myeloid leukemia: current concepts and future goals. Expert Rev. Clin. Immunol. 11, 511\u2013522 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"27928_CR71","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013702 (2017).","journal-title":"Nat. Med."},{"key":"27928_CR72","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cncr.32627","volume":"126","author":"A Maiti","year":"2020","unstructured":"Maiti, A. et al. Long\u2010term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126, 1502\u20131511 (2020).","journal-title":"Cancer"},{"key":"27928_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi, K. et al. Long\u2010term follow\u2010up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic\u2010phase chronic myeloid leukemia. Cancer 126, 67\u201375 (2020).","journal-title":"Cancer"},{"key":"27928_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-137734","volume":"136","author":"AM Zeidan","year":"2020","unstructured":"Zeidan, A. M. et al. Blast MRD CML 1 Trial: blockade of PD-1 added to standard therapy to target measurable residual disease (MRD) in chronic myeloid leukemia (CML)- a phase II study of adding the anti-PD-1 pembrolizumab to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease: a trial of the ECOG-ACRIN Cancer Research Group (EA9171). Blood 136, 1\u20131 (2020).","journal-title":"Blood"},{"key":"27928_CR75","doi-asserted-by":"publisher","first-page":"584626","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli, F. et al. Regulation of PD-L1 expression by NF-\u03baB in cancer. Front. Immunol. 11, 584626 (2020).","journal-title":"Front. Immunol."},{"key":"27928_CR76","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1158\/0008-5472.CAN-18-3134","volume":"79","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-\u03baB contributes to UV radiation-induced immune suppression. Cancer Res. 79, 2909\u20132922 (2019).","journal-title":"Cancer Res."},{"key":"27928_CR77","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang, C.-H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"27928_CR78","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark, C. A. et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76, 6964\u20136974 (2016).","journal-title":"Cancer Res."},{"key":"27928_CR79","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/sigtrans.2016.30","volume":"1","author":"HB Gupta","year":"2016","unstructured":"Gupta, H. B. et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct. Target. Ther. 1, 16030 (2016).","journal-title":"Signal Transduct. Target. Ther."},{"key":"27928_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02866-0","volume":"9","author":"T Hayashi","year":"2018","unstructured":"Hayashi, T. et al. Single-cell full-length total RNA sequencing uncovers dynamics of recursive splicing and enhancer RNAs. Nat. Commun. 9, 619 (2018).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27928-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27928-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27928-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:46:42Z","timestamp":1669286802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27928-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27928"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27928-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-449398\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"1 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}